Maxomega-90 Omega-3 Launch: A ‘Blank Canvas’ For Formulators

Scottish firm Equateq announces today that high-end nutraceutical companies can now provide their customers with almost any ratio of EPA and DHA omega oil concentrates they want, with the launch of Maxomega-90, a range that exploits pharmaceutical sector separation methods to deliver omega-3 EPA and DHA in any 90% combination, Equateq announced today.

‘We say that Maxomega-90 is like a blank canvas, allowing companies to mix lipid actives in almost any combination they require,’ explained Equateq CEO Adam Kelliher. ‘This will enable companies to define their product rationale and give a more clear, and focused offering.’

Lipid specialist Equateq is unique in using industrial-scale chromatography to make lipid concentrates, in preference to the usual industry method of distillation. The Maxomega ™ process can separate all key lipids at up to 99% purity, but these super-high levels are mostly used by pharmaceutical companies and researchers. The Maxomega-90 range is geared for the nutritional sector, allowing delivery of EPA and DHA in any ratio, from 80/10 to 10/80, with each offering always having at least 90% total omega-3.

More info